Stacie Weninger

Stacie Weninger is a Venture Partner at F-Prime Capital and President of the F-Prime Biomedical Research Initiative based in Cambridge, Massachusetts. With more than 20 years of experience in the biotechnology sector, she previously served as Senior Director of Science Programs at the Fidelity Foundations and held analytical roles at Harvard University. Weninger has acted as a founding board member for publicly traded biotechnology companies including Denali Therapeutics and Neumora Therapeutics, while also holding board seats at Annexon Biosciences and Target ALS. She holds a doctorate and began her career as a postdoctoral research fellow at Harvard Medical School before working as a Senior Scientific Editor for the journal Neuron. Her current investment and operational focus centers on translating early scientific discoveries into novel precision medicines and therapeutics for neurodegenerative and psychiatric disorders.